Orexo AB (publ) (STO:ORX)
27.80
-0.50 (-1.77%)
Oct 31, 2025, 12:59 PM CET
Orexo AB Employees
Orexo AB had 110 employees as of December 31, 2024. The number of employees decreased by 6 or -5.17% compared to the previous year.
Employees
110
Change (1Y)
-6
Growth (1Y)
-5.17%
Revenue / Employee
5.23M SEK
Profits / Employee
-1.94M SEK
Market Cap
954.32M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 110 | -6 | -5.17% |
| Dec 31, 2023 | 116 | -10 | -7.94% |
| Dec 31, 2022 | 126 | 7 | 5.88% |
| Dec 31, 2021 | 119 | -18 | -13.14% |
| Dec 31, 2020 | 137 | 10 | 7.87% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Medicover AB | 47,256 |
| Getinge AB | 11,791 |
| Nolato AB | 5,837 |
| Elekta AB | 4,556 |
| Asker Healthcare Group AB | 4,030 |
| AddLife AB | 2,181 |
| Swedish Orphan Biovitrum AB | 1,806 |
| Sectra AB | 1,296 |
Orexo AB News
- 9 days ago - Orexo AB (publ) (ORXOY) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication - PRNewsWire
- 5 months ago - Orexo to present clinical data for OX640 at the EAACI Congress - PRNewsWire
- 7 months ago - Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology - PRNewsWire
- 10 months ago - Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis - PRNewsWire
- 11 months ago - Orexo, Abera to develop nasal powder vaccines based on AmorphOX technology - Seeking Alpha
- 11 months ago - Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology - PRNewsWire
- 1 year ago - Orexo initiates new study of OX640 in participants with allergic rhinitis - PRNewsWire